Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Fong

Showing results (451-460 of 468) with videos related to

Pageof 47
Sort By:
Current Environmental Health Reports|August 20, 2025
Metrics of Urbanicity and Rurality in US-Based Epidemiologic Studies of Ambient Temperature and Health: A Scoping ReviewNicholaus P Johnson, Alexandra Del Favero-Campbell, Amruta Nori-Sarma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2020
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian CarcinomaAmit M Oza, Domenica Lorusso, Carol Aghajanian, et al.
Bioorganic & Medicinal Chemistry Letters|May 8, 2007
Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safetyTimothy I Richardson, Scott A Frank, Minmin Wang, et al.
JCI Insight|February 23, 2018
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumorsStergios J Moschos, Ryan J Sullivan, Wen-Jen Hwu, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2025
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trialJonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
Neurology|June 8, 2019
Age at onset in genetic prion disease and the design of preventive clinical trialsEric Vallabh Minikel, Sonia M Vallabh, Margaret C Orseth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2023
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 TrialEmmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh, et al.
Neurology|May 18, 2022
Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal DementiaGianina Toller, Yann Cobigo, Peter A Ljubenkov, et al.
Circulation|March 27, 2023
Impaired Reorganization of Centrosome Structure Underlies Human Infantile Dilated CardiomyopathyYoung Wook Chun, Matthew Miyamoto, Charles H Williams, et al.
Lancet (London, England)|September 17, 2017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialRobert L Coleman, Amit M Oza, Domenica Lorusso, et al.
Pageof 47

Showing results (451-460 of 468) with videos related to

Sort By:
Pageof 47
Current Environmental Health Reports|August 20, 2025
Metrics of Urbanicity and Rurality in US-Based Epidemiologic Studies of Ambient Temperature and Health: A Scoping ReviewNicholaus P Johnson, Alexandra Del Favero-Campbell, Amruta Nori-Sarma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2020
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian CarcinomaAmit M Oza, Domenica Lorusso, Carol Aghajanian, et al.
Bioorganic & Medicinal Chemistry Letters|May 8, 2007
Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safetyTimothy I Richardson, Scott A Frank, Minmin Wang, et al.
JCI Insight|February 23, 2018
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumorsStergios J Moschos, Ryan J Sullivan, Wen-Jen Hwu, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2025
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trialJonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
Neurology|June 8, 2019
Age at onset in genetic prion disease and the design of preventive clinical trialsEric Vallabh Minikel, Sonia M Vallabh, Margaret C Orseth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2023
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 TrialEmmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh, et al.
Neurology|May 18, 2022
Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal DementiaGianina Toller, Yann Cobigo, Peter A Ljubenkov, et al.
Circulation|March 27, 2023
Impaired Reorganization of Centrosome Structure Underlies Human Infantile Dilated CardiomyopathyYoung Wook Chun, Matthew Miyamoto, Charles H Williams, et al.
Lancet (London, England)|September 17, 2017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialRobert L Coleman, Amit M Oza, Domenica Lorusso, et al.
Pageof 47